Strategic Partnership Aldevron operates as part of Danaher, enabling access to a broad network of biopharma clients and potential cross-sell opportunities across biotechnology, diagnostics, and life sciences. Leverage Danaher affiliation to approach mutual customers with integrated solutions in DNA, RNA, and protein production.

Genome Manufacturing Strong focus on plasmid DNA, mRNA, and protein production positions Aldevron as a partner for gene therapy, vaccine development, and genomic medicine programs. Target biotech firms advancing mRNA therapeutics, cell therapy, and viral vector work that require scalable GMP manufacturing.

Strategic Collaborations Recent and ongoing partnerships (Minaris, TriLink, InDevR, Acuitas, Codexis licensing) indicate a pattern of collaboration to broaden capabilities and access. Use co-selling and joint development approaches with potential partners and customers pursuing complementary technologies.

CDMO Leadership Recognition as a 2026 CDMO Leadership Awards winner signals credibility in small to mid-size cell and gene therapy segments. Position Aldevron to mid-market biotech companies seeking validated contract development and manufacturing services with proven quality and scale.

Financial Scale Revenue in the mid-range of hundreds of millions and a sizable employee base suggest established capacity and investment in expansion. Pursue opportunities with growing biotech startups and mid-stage programs needing reliable supply of plasmid DNA, mRNA, and related reagents at scale.